Navigation Links
Hormone refractory prostate cancers more likely to spread to other organs
Date:2/20/2008

Prostate cancers that are resistant to androgen deprivation therapy are more invasive and more likely to spread to other organs than androgen dependent prostate cancers, UCLA cancer researchers have found.

Virtually all prostate cancers are androgen dependent at first, but they progress and become resistant over time. These hormone refractory or castration resistant cancers can grow despite surgical or medical therapies that deplete testosterone. The UCLA study is the first to link that progression with the cancers tendency to spread to other organs. The findings could change the way some prostate cancers are treated, spurring earlier use of hormone therapy to prevent the cancers spread, said Dr. Robert Reiter, a professor of urology, a researcher at UCLAs Jonsson Cancer Center and senior author of the study.

Published in the Feb. 15 issue of the journal Cancer Research, the study makes the connection between androgen receptor and the spread of prostate cancer as well as the progression to androgen independence. Previous studies have shown that the androgen receptor is responsible for the growth of hormone refractory prostate cancer. However, no one has associated the spread of prostate cancer to the androgen receptor, Reiter said.

We started noticing that the castration resistant prostate cancer models in the lab seemed to express genes that are typically associated with the spread of cancer, Reiter said. We began to ask what cell signaling pathways might be responsible. We looked at the androgen receptor and were surprised to find that it was not only overexpressed in castration resistant cancers but also in invasive cancers that still relied on androgen to grow.

The study found that overexpression of the androgen receptor was critical to the cancer becoming more invasive. If a therapy could be found that blocked overexpression of the receptor, it might prevent the spread of certain prostate cancers.

Traditionally, doctors dont like to use hormone treatment which stops the production of testosterone - early on in the treatment of prostate cancer because of the harsh side effects, which can include hot flashes, osteoporosis and sexual dysfunction. In the past, doctors have waited until the cancer spread to prescribe hormone therapy, Reiter said.

This study may provide additional scientific rationale to support the recent trend that giving hormone treatment early on is better than waiting, Reiter said. Early hormone treatment in this group of men might allow them to live longer. High levels of androgen receptor in the primary tumor might also predict which cancers are more likely to spread despite initial surgery or radiation.

This strategy could be particularly effective in high risk men, those with large primary tumors, high Gleason scores and those that have lymph node involvement at diagnosis.

Prostate cancer is the most common cancer in men in the United States. This year alone, more than 218,000 men will be diagnosed with prostate cancer. About 27,000 men will die from the disease.

Reiter and his team will next seek to understand the mechanism by which androgen receptor overexpression is causing the cancer to spread. If they can uncover the mechanism, they might find new and better targets for drug therapy in addition to targeting the androgen receptor.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Newly discovered role of thyroid hormone during pregnancy
2. Stress hormone impacts memory, learning in diabetic rodents
3. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
4. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
5. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
6. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
7. FDA Warns Against Bio-Identical Hormone Therapy
8. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
9. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
10. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
11. Hormone may be new drug target for preventing lymphedema, tumor spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Spectrum Aquatics has launched a brand new ... designed and built with the user in mind. , “Over the last two years ... that an ADA 400 lbs lift is a necessary requirement for certain facilities with ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... media enterprise focused on patients with cancer, has added Cancer and Careers ... website visitors with more timely content on continuing successful careers while fighting cancer. ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute ... 8-day-8 and 8-night special intensive summer training camp starts on June 17th on ... offers families and children a fun and unique experience with an opportunity to ...
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... day issues, struggles and obstacles veterans’ need to overcome in order to face their ... or retired military veteran(s) with a donated SuperCloset product based on the needs and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
(Date:5/25/2016)... 2016 MedDay, a biotechnology company focused ... oral presentation entitled "High doses of biotin in progressive multiple ... given by Professor Ayman Tourbah , Principal Investigator of ... European Academy of Neurology (EAN) in Copenhagen, Denmark ... will take place on Sunday, 29 May 2016 from 14:45 ...
Breaking Medicine Technology: